About the study The clinical trial involved healthy adults aged 19 to 40, with a Body mass index (BMI) between 18.5 and 25 kg/m, who had consumed alcohol at least once a month and experienced hangover symptoms
The recommended starting dose is 0.25 mg per day, and the dose is slowly increased over four weeks until it reaches the maintenance dose
As of 2026, no peer-reviewed human RCT (Randomised Controlled Trial) has tested subcutaneous GHK-Cu administration [7][9]
Anything that is administered intravenously needs to have a higher level of caution, Mulvihill shares
I think thats where the world is rapidly heading, just because its so clear and obvious and definitive that with nothing, regain is the path, Duffy said
In clinical trials, significant weight loss is typically seen at the 12-to-16-week mark